Natixis Advisors LLC Has $135.40 Million Holdings in Novo Nordisk A/S $NVO

Natixis Advisors LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,661,238 shares of the company’s stock after purchasing an additional 105,703 shares during the quarter. Natixis Advisors LLC’s holdings in Novo Nordisk A/S were worth $135,404,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in NVO. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $314,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on NVO. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Finally, Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its Wegovy pill will launch in the UAE after receiving regulatory approval, another sign that its oral obesity treatment is gaining international traction. Novo Nordisk’s Wegovy Pill to Launch in the UAE Following Regulatory Approval
• Positive Sentiment: Novo Nordisk announced a partnership with NOVI Health in Singapore to expand access to structured weight-care support, which could help broaden adoption of its obesity treatments. NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore
• Positive Sentiment: Novo Nordisk continued its share repurchase program, a move that can support earnings per share and signal management confidence. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Investors are also watching Novo Nordisk ahead of the ADA conference, where any new diabetes or obesity updates could influence sentiment. Is Novo Nordisk A/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?
• Neutral Sentiment: Analysts are highlighting broader long-term growth potential in GLP-1 drugs, but this is more of a thematic backdrop than a direct catalyst. 5 Best Growth Stocks for the Next 10 Years (NVO)
• Negative Sentiment: Eli Lilly regained CVS Health’s support for GLP-1 access, which may weaken Novo Nordisk’s competitive position in the U.S. obesity-drug market. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage (NVO)
• Negative Sentiment: Tracking data suggests Wegovy’s oral version is still leading Lilly’s rival tablet, but weekly prescription growth is slowing as competition heats up in the GLP-1 space. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows

Novo Nordisk A/S Trading Down 2.6%

Shares of NVO stock opened at $42.93 on Wednesday. The company has a market cap of $191.70 billion, a P/E ratio of 10.08, a PEG ratio of 3.93 and a beta of 0.78. The stock has a 50 day simple moving average of $41.12 and a two-hundred day simple moving average of $46.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Research analysts forecast that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.